S. Gore

H. Deeg, J. Bennett, S. Gore, 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Risk stratification in myelodysplastic syndromes: is there a role for gene expression profiling?

S. Gore, A. Zeidan, T. Prebet, 2014, Expert review of hematology.

Central Role of Fas-associated Death Domain Protein in Apoptosis Induction by the Mitogen-activated Protein Kinase Kinase Inhibitor CI-1040 (PD184352) in Acute Lymphocytic Leukemia Cells in Vitro*

J. Sebolt-Leopold, D. Loegering, J. Karp, 2003, Journal of Biological Chemistry.

Management of High-Risk Myelodysplastic Syndrome

S. Gore, A. Zeidan, 2013 .

Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias.

E. Sausville, J. Karp, J. Trepel, 2007, Blood.

Steel factor supports the cycling of isolated human CD34+ cells in the absence of other growth factors.

L. Weng, C. Civin, S. Gore, 1995, Experimental hematology.

Elevated expression of the apoptotic regulator Mcl-1 at the time of leukemic relapse.

John Calvin Reed, S. Krajewski, J. Karp, 1998, Blood.

Epigenetic therapies in MDS and AML.

S. Gore, E. Griffiths, 2013, Advances in experimental medicine and biology.

Impact of Hydroxyurea on Survival and Risk of Thrombosis Among Older Patients With Essential Thrombocythemia.

Xiaomei Ma, S. Gore, A. Zeidan, 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

Physician Experience and Risk of Rituximab Discontinuation in Older Adults With Non-Hodgkin's Lymphoma.

C. Gross, Xiaomei Ma, S. Gore, 2019, Journal of the National Comprehensive Cancer Network : JNCCN.

Patterns of erythropoiesis-stimulating agent use among Medicare beneficiaries with myelodysplastic syndromes and consistency with clinical guidelines.

S. Gore, S. Weiss, M. Baer, 2013, Leukemia research.

Real-life experience of a brief arsenic trioxide-based consolidation chemotherapy in the management of acute promyelocytic leukemia: favorable outcomes with limited anthracycline exposure and shorter consolidation therapy.

S. Solomon, B. Smith, S. Gore, 2015, Clinical Lymphoma, Myeloma & Leukemia.

Cui bono? Finding the value of allogeneic stem cell transplantation for lower-risk myelodysplastic syndromes

S. Gore, A. Zeidan, R. Shallis, 2020, Expert review of hematology.

Hypomethylating agents (HMA) treatment for myelodysplastic syndromes: alternatives in the frontline and relapse settings

S. Gore, T. Prebet, N. Uy, 2017, Expert opinion on pharmacotherapy.

The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort.

Alexandra G. Smith, J. Maciejewski, D. Steensma, 2018, Blood advances.

Outcome of patients treated for myelodysplastic syndromes without deletion 5q after failure of lenalidomide therapy

P. Fenaux, T. Cluzeau, S. Gore, 2017, Oncotarget.

Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117.

C. Bloomfield, F. Appelbaum, R. Stone, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides

J. Barnard, H. Kantarjian, G. Garcia-Manero, 2016, Leukemia.

Azacitidine with or without Entinostat for the treatment of therapy‐related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study

J. Herman, J. Gabrilove, P. Greenberg, 2016, British journal of haematology.

Current state of prognostication and risk stratification in myelodysplastic syndromes

S. Gore, E. Padron, A. Zeidan, 2015, Current opinion in hematology.

Bone marrow hypocellularity does not affect tolerance or efficacy of azacitidine in patients with higher‐risk myelodysplastic syndromes

G. Mufti, B. Skikne, J. Bennett, 2014, British journal of haematology.

Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine‐treated patients with myelodysplastic syndromes

J. Gabrilove, P. Greenberg, M. Tallman, 2014, British journal of haematology.

Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSS

J. Gabrilove, P. Greenberg, M. Tallman, 2014, British journal of haematology.

Prognostication in myelodysplastic syndromes: beyond the International Prognostic Scoring System (IPSS).

B. Smith, S. Gore, A. Zeidan, 2013, The American journal of medicine.

Myelodysplastic syndromes: what do hospitalists need to know?

S. Gore, B. Faltas, A. Zeidan, 2013, Journal of hospital medicine.

Iron chelation therapy in myelodysplastic syndromes: where do we stand?

S. Gore, A. Zeidan, Mhairi Mitchell, 2013, Expert review of hematology.

Should elderly patients with higher-risk myelodysplastic syndromes undergo allogeneic hematopoietic stem cell transplantation?

S. Gore, A. Zeidan, 2013, Expert review of hematology.

Intensity of end‐of‐life care for patients with myelodysplastic syndromes: Findings from a large national database

G. Abel, O. Odejide, D. Steensma, 2016, Cancer.

Treatment and outcomes for chronic myelomonocytic leukemia compared to myelodysplastic syndromes in older adults

S. Gore, M. Baer, A. Davidoff, 2013, Haematologica.

NCCN Task Force: Transfusion and iron overload in patients with myelodysplastic syndromes.

M. Millenson, H. Deeg, Rashmi Kumar, 2009, Journal of the National Comprehensive Cancer Network : JNCCN.

Myelodysplastic syndromes clinical practice guidelines in oncology.

C. Bloomfield, M. Millenson, H. Deeg, 2006, Journal of the National Comprehensive Cancer Network : JNCCN.

Cost‐effectiveness analysis of consolidation with brentuximab vedotin for high‐risk Hodgkin lymphoma after autologous stem cell transplantation

Xiaomei Ma, S. Gore, A. Zeidan, 2017, Cancer.

In vitro basis for treatment with hypomethylating agents and histone deacetylase inhibitors: can epigenetic changes be used to monitor treatment?

S. Gore, 2009, Leukemia research.

Biologically Based Treatment

S. Gore, Philip J Nivatpumin, 2006 .

Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multi-center, international study

M. Tormo, C. McMahon, T. Cluzeau, 2020, Leukemia.

Single agent blinatumumab as frontline therapy for an 85-year-old patient with B cell precursor acute lymphoblastic leukemia

Tae Kon Kim, S. Gore, A. Zeidan, 2016, Annals of Hematology.

Association Between Ownership of Imaging Equipment and Appropriateness of Staging Positron-Emission Tomography in Non-Hodgkin Lymphoma

C. Gross, Xiaomei Ma, S. Gore, 2019, JNCI cancer spectrum.

CancerNet: a unified deep learning network for pan-cancer diagnostics

S. Gore, R. Azad, 2022, BMC Bioinformatics.

Patient and physician characteristics associated with erythropoiesis-stimulating agent use in patients with myelodysplastic syndromes

S. Gore, M. Baer, A. Davidoff, 2012, Haematologica.

Challenges of phase III trial design for novel treatments in diseases with no standard treatment: the AZA-001 myelodysplasia study model.

E. Estey, L. Silverman, G. Mufti, 2014, Leukemia research.

A phase II trial of three sequential doublets for the treatment of advanced müllerian malignancies.

R. Berkowitz, U. Matulonis, S. Gore, 2003, Gynecologic oncology.

Development of Epigenetic Targeted Therapies in Hematological Malignancies: From Serendipity to Synthetic Lethality

S. Gore, T. Prebet, Thomas Prebet, 2015 .

Normal human bone marrow precursors that express terminal deoxynucleotidyl transferase include T-cell precursors and possible lymphoid stem cells.

M. Kastan, C. Civin, S. Gore, 1991, Blood.

Progress in differentiation induction as a treatment for acute promyelocytic leukemia and beyond.

A. Kimchi, M. Carducci, A. Zelent, 2002, Cancer research.

Erythropoiesis-stimulating agents are not associated with increased risk of thrombosis in patients with myelodysplastic syndromes

S. Gore, M. Baer, A. Davidoff, 2012, Haematologica.

Wide variation in use and interpretation of gene mutation profiling panels among health care providers of patients with myelodysplastic syndromes: results of a large web-based survey

R. Bejar, P. Greenberg, D. Steensma, 2020, Leukemia & lymphoma.

Outcome of patients treated for myelodysplastic syndromes with 5q deletion after failure of lenalidomide therapy

P. Fenaux, T. Cluzeau, L. Adès, 2017, OncoTarget.

A phase II "window" study of topotecan in untreated patients with high risk adult acute lymphoblastic leukemia.

M. Grever, M. Borowitz, R. Donehower, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Chromosome 1 abnormalities and survival of patients with multiple myeloma in the era of novel agents.

C. Gross, Xiaomei Ma, S. Gore, 2020, Blood advances.

Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes

B. Skikne, S. Kambhampati, G. Garcia-Manero, 2015, Leukemia.

A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial

J. Bennett, P. Fenaux, E. Hellström-Lindberg, 2013, Haematologica.

Wide variations in blood product transfusion practices among providers who care for patients with acute leukemia in the United States

D. Zelterman, G. Garcia-Manero, D. Steensma, 2017, Transfusion.

A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating Agent Failure

E. Warren, Y. Levy, B. Smith, 2018, Clinical Cancer Research.

A multi-center Phase 1 trial of ipilimumab in myelodysplastic syndrome patients following hypomethylating agent failure

B. Smith, S. Gore, A. Blackford, 2018 .

Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905.

J. Herman, J. Gabrilove, A. Melnick, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine *

G. Mufti, P. Fenaux, E. Hellström-Lindberg, 2010, European journal of haematology.

Prolonged survival with improved tolerability in higher‐risk myelodysplastic syndromes: azacitidine compared with low dose ara‐C

G. Mufti, P. Fenaux, E. Hellström-Lindberg, 2010, British journal of haematology.

Epigenetic differences in cytogenetically normal versus abnormal acute myeloid leukemia

J. Herman, M. McDevitt, B. Smith, 2010, Epigenetics.

Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher‐risk myelodysplastic syndromes

G. Mufti, P. Fenaux, E. Hellström-Lindberg, 2011, Cancer.

Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia.

L. Grochow, R. Donehower, S. Kaufmann, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Patient cost sharing and receipt of erythropoiesis-stimulating agents through medicare part D.

S. Gore, B. Stuart, M. Baer, 2015, Journal of oncology practice.

Addition of histone deacetylase inhibitors in combination therapy.

S. Gore, H. Carraway, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia.

M. Grever, L. Grochow, R. Donehower, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Myelodysplastic syndromes: where do we go from here?

S. Gore, H. Carraway, 2011, Oncology.

A call for action: Increasing enrollment of untreated patients with higher‐risk myelodysplastic syndromes in first‐line clinical trials

D. Steensma, S. Gore, M. Sekeres, 2017, Cancer.

Variations in erythropoiesis-stimulating agent administration in transfusion-dependent myelodysplastic syndromes impact response.

S. Gore, S. Weiss, M. Baer, 2015, Leukemia research.

Effect of erythropoiesis-stimulating agent policy decisions on off-label use in myelodysplastic syndromes.

S. Gore, M. Baer, A. Zeidan, 2014, Medicare & medicaid research review.

Lenalidomide performance in the real world

S. Gore, M. Baer, A. Zeidan, 2013, Cancer.

Prolonged Administration of Azacitidine with or without Entinostat Increases Rate of Hematologic Normalization for Myelodysplastic Syndrome and Acute Myeloid Leukemia with Myelodysplasia-Related Changes: Results of the US Leukemia Intergroup Trial E1905

J. Gabrilove, P. Greenberg, M. Tallman, 2010 .

Azacitidine (AZA) Treatment Prolongs Overall Survival (OS) in Higher-Risk MDS Patients Compared with Conventional Care Regimens (CCR): Results of the AZA-001 Phase III Study.

J. Byrd, G. Mufti, J. Bennett, 2007 .

Additional Analyses of a Randomized Phase II Study of Azacitidine Combined with Lenalidomide or with Vorinostat Vs. Azacitidine Monotherapy in Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML): North American Intergroup Study SWOG S1117

C. Bloomfield, F. Appelbaum, R. Stone, 2014 .

RBC transfusion independence among lower risk MDS patients receiving hypomethylating agents: a population-level analysis

Xiaomei Ma, S. Gore, A. Zeidan, 2019, Leukemia & lymphoma.

Counseling patients with higher-risk MDS regarding survival with azacitidine therapy: are we using realistic estimates?

Xiaomei Ma, S. Gore, A. Zeidan, 2018, Blood Cancer Journal.

Time-dependent decision analysis: Stable disease in azacitidine (AZA)-treated patients (pts) with higher-risk MDS.

J. Bennett, P. Fenaux, E. Hellström-Lindberg, 2010 .

Effect of azacitidine (AZA) on overall survival in higher-risk myelodysplastic syndromes (MDS) without complete remission

G. Mufti, J. Bennett, P. Fenaux, 2008 .

NCCN practice guidelines for the myelodysplastic syndromes

E. Estey, P. Greenberg, J. Bennett, 1998 .

Outcome of Patients Treated for Myelodysplastic Syndromes after Failure of Lenalidomide Therapy

P. Fenaux, T. Cluzeau, L. Adès, 2015 .

High dose cyclophosphamide for cytoreduction in patients with acute myeloid leukemia with hyperleukocytosis or leukostasis

S. Gore, J. Bewersdorf, A. Zeidan, 2020, Leukemia & lymphoma.

Patterns of care and clinical outcomes of patients with newly diagnosed acute myeloid leukemia presenting with hyperleukocytosis who do not receive intensive chemotherapy

M. Tormo, C. McMahon, T. Cluzeau, 2020, Leukemia & lymphoma.

Beliefs and practice patterns in hyperleukocytosis management in acute myeloid leukemia: a large U.S. web-based survey*

Tae Kon Kim, D. Steensma, R. Stone, 2018, Leukemia & lymphoma.

Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort.

Tae Kon Kim, J. Barnard, P. Fenaux, 2018, Blood advances.

New agents for the treatment of AML recent study findings.

S. Gore, 2008, Clinical advances in hematology & oncology : H&O.

Influence of Karyotype On Overall Survival in Patients with Higher-Risk Myelodysplastic Syndrome Treated with Azacitidine or a Conventional Care Regimen.

A. Hagemeijer, G. Mufti, B. Skikne, 2009 .

Outcome of acute myeloid leukaemia following myelodysplastic syndrome after azacitidine treatment failure

B. Esterni, B. Quesnel, P. Fenaux, 2012, British journal of haematology.

Combination therapy with DNA methyltransferase inhibitors in hematologic malignancies

S. Gore, 2005, Nature Clinical Practice Oncology.

Multi-institutional phase 2 clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemia.

Yixin Wang, S. Malek, M. McDevitt, 2012, Blood.

The Effects of Continued Azacitidine (AZA) Treatment Cycles on Response in Higher-Risk Patients (Pts) with Myelodysplastic Syndromes (MDS)

G. Mufti, P. Fenaux, E. Hellström-Lindberg, 2008 .

Treatment of high-risk MDS patients (pts) with -7/del(7q) with azacitidine (AZA) versus conventional care regimens (CCR): Effects on overall survival (OS)

G. Mufti, P. Fenaux, E. Hellström-Lindberg, 2008 .

Myelodysplastic syndromes: clinical practice guidelines in oncology.

C. Bloomfield, M. Millenson, H. Deeg, 2013, Journal of the National Comprehensive Cancer Network : JNCCN.

Autologous bone marrow transplantation with 4‐hydroperoxycyclophosphamide purging for acute myeloid leukaemia beyond first remission: a 10‐year experience

I. Flinn, S. Piantadosi, Richard J. Jones, 2002, British journal of haematology.

Treatment of acute promyelocytic leukemia for older patients.

S. Gore, T. Prebet, 2011, Journal of the National Comprehensive Cancer Network : JNCCN.

Higher-risk myelodysplastic syndromes with del(5q): is sequential azacitidine–lenalidomide combination the way to go?

S. Gore, A. Zeidan, R. Komrokji, 2013, Expert review of hematology.

Lenalidomide Performance in the Real World: Patterns of Utilization and Effectiveness in a Medicare Population with Myelodysplastic Syndromes

S. Gore, M. Baer, A. Zeidan, 2012 .

A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Patients with Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML).

B. Skikne, G. Garcia-Manero, S. Gore, 2009 .

Clinical evaluation of combined azacitidine and entinostat on the induction of fetal hemoglobin in patients with acute myeloid leukemias and myelodysplastic syndromes

J. Keefer, S. Gore, H. Carraway, 2018, Leukemia & lymphoma.

Azacitidine Prolongs Overall Survival (OS) and Reduces Infections and Hospitalizations in Patients (Pts) with WHO-Defined Acute Myeloid Leukemia (AML) Compared with Conventional Care Regimens (CCR)

L. Silverman, G. Mufti, P. Fenaux, 2008 .

CC-486 (Oral Azacitidine) in Patients with Hematological Malignancies Who Had Received Prior Treatment with Injectable Hypomethylating Agents (HMAs): Results from Phase 1/2 CC-486 Studies

B. Skikne, G. Garcia-Manero, S. Gore, 2016 .

Hematologic malignancies : myelodysplastic syndromes

H. Deeg, M. L. Beau, T. Haferlach, 2006 .

Outcome of patients with low-risk myelodysplasia after azacitidine treatment failure

P. Fenaux, S. Thépot, S. Gore, 2013, Haematologica.

A 10 Day Schedule of Azacitidine Induces More Complete Cytogenetic Remissions Than the Standard Schedule In Myelodysplasia and Acute Myeloid Leukemia with Myelodysplasia-Related Changes: Results of the E1905 US Leukemia Intergroup Study

J. Gabrilove, P. Greenberg, M. Tallman, 2010 .

The Use of Immunosuppressive Therapy (IST) in Patients with the Myelodysplastic Syndromes (MDS): Clinical Outcomes and Their Predictors in a Large International Patient Cohort

L. Arenillas, D. Steensma, P. Fenaux, 2017 .

Allogeneic Hematopoietic Stem Cell Transplantation Following the Use of Hypomethylating Agents among Patients with Relapsed or Refractory AML: Findings from an International Retrospective Study.

Tae Kon Kim, J. Barnard, P. Fenaux, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

inhibitor, in adults with refractory and relapsed acute leukemias Phase 1 and pharmacologic study of MS-275, a histone deacetylase

J. Karp, J. Trepel, A. Sparreboom, 2013 .

A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic Leukemia

G. Rosner, J. Herman, M. McDevitt, 2016, Clinical Cancer Research.

Phase I and Pharmacologic Trial of Cytosine Arabinoside with the Selective Checkpoint 1 Inhibitor Sch 900776 in Refractory Acute Leukemias

M. McDevitt, K. Flatten, B. Smith, 2012, Clinical Cancer Research.

Stage-specific application of allogeneic and autologous marrow transplantation in the management of acute myeloid leukemia.

S. Gore, W. Edenfield, 1999, Seminars in oncology.

Effects of Azacitidine (AZA) Vs Conventional Care Regimens (CCR) in Elderly (≥75 years) Patients (Pts) with Myelodysplastic Syndromes (MDS) from the AZA-001 Survival Trial

L. Silverman, G. Mufti, P. Fenaux, 2008 .

The Use of Hypomethylating Agents (HMAs) in Patients with Relapsed and Refractory Acute Myeloid Leukemia (RR-AML): Clinical Outcomes and Their Predictors in a Large International Patient Cohort

Tae Kon Kim, D. Zelterman, P. Fenaux, 2016 .

Stabilization of Myelodysplastic Syndromes (MDS) Following Hypomethylating Agent (HMAs) Failure Using the Immune Checkpoint Inhibitor Ipilimumab: A Phase I Trial

B. Smith, S. Gore, I. Gojo, 2015 .

Patterns of care and clinical outcomes with cytarabine-anthracycline induction chemotherapy for AML patients in the United States.

Xiaomei Ma, S. Gore, J. Bewersdorf, 2020, Blood advances.

A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasms

M. McDevitt, B. Smith, J. Karp, 2014, Haematologica.

Evidence for the regulation of luteinizing hormone-sensitive adenylate cyclase by mono- and divalent cations

S. Gore, 1984 .

Clinical Effectiveness of Hypomethylating Agents (HMAs) and Lenalidomide (Len) in Older Patients (pts) with Refractory Anemia with Ring Sideroblasts: A Large Population-Based Study in the United States (US)

Xiaomei Ma, S. Gore, A. Zeidan, 2019, Blood.

Combined Methyltransferase/Histone Deacetylase Inhibition with 5-Azacitidine and MS-275 in Patients with MDS, CMMoL and AML: Clinical Response, Histone Acetylation and DNA Damage.

J. Herman, S. Baylin, J. Licht, 2006 .

Topoisomerase II and the response to antileukemic therapy.

L. Zwelling, J. Karp, S. Kaufmann, 1998, Leukemia & lymphoma.

A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias.

M. McDevitt, B. Smith, J. Karp, 2007, Blood.

DNA methyltransferase inhibitors: Class effect or unique agents?

S. Gore, E. Griffiths, 2008, Leukemia & lymphoma.

Altered formation of topotecan-stabilized topoisomerase I-DNA adducts in human leukemia cells.

S. Kaufmann, Y. Cheng, P. Svingen, 1997, Blood.

5-azacytidine as salvage treatment in relapsed myeloid tumors after allogeneic bone marrow transplantation.

M. McDevitt, Richard J. Jones, B. Smith, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Antigenic analysis of hematopoiesis: a review.

C. Civin, S. Gore, 1993, Journal of hematotherapy.

Outcome of patients treated for myelodysplastic syndromes with 5q deletion after failure of lenalidomide therapy.

P. Fenaux, T. Cluzeau, L. Adès, 2017, OncoTarget.

Validation of flow-cytometric determination of Ki67 expression as a measure of growth factor response in acute myelogenous leukemia.

L. Weng, S. Gore, P. Burke, 1993, Experimental hematology.

Cp-jeez! Aza-natomy!

S. Gore, L. Suarez, 2012, Blood.

2354 2 0 S E P T E M B E R 2 0 1 2 I V O L U M E 1 2 0 , N U M B E R 1 2 Blood

S. Gore, 2022 .

Phase 1 dose‐escalation trial of clofarabine followed by escalating dose of fractionated cyclophosphamide in adults with relapsed or refractory acute leukaemias

M. McDevitt, B. Smith, J. Karp, 2012, British journal of haematology.

Evaluation of Oral Azacitidine Using Extended Treatment Schedules: A Phase I Study

B. Skikne, H. Kantarjian, G. Garcia-Manero, 2010 .

Patterns of Venous Thromboembolism Prophylaxis During Treatment of Acute Leukemia: Results of a North American Web-Based Survey.

B. Smith, Eun-Ju Lee, S. Gore, 2015, Clinical lymphoma, myeloma & leukemia.

Challenges in the Evaluation and Management of Toxicities Arising From Immune Checkpoint Inhibitor Therapy for Patients With Myeloid Malignancies.

S. Gore, S. Halene, J. Bewersdorf, 2021, Clinical lymphoma, myeloma & leukemia.

Addition of etoposide to initial therapy of adult acute lymphoblastic leukemia: a combined clinical and laboratory study.

J. Karp, S. Kaufmann, S. Gore, 1996, Leukemia & lymphoma.

Chromosome 1 abnormalities and clinical outcomes in multiple myeloma in the era of novel agents.

C. Gross, Xiaomei Ma, S. Gore, 2019, Journal of Clinical Oncology.

Leukemic Relapse Elevated Expression of the Apoptotic Regulator Mcl-1 at the Time of

John Calvin Reed, S. Krajewski, J. Karp, 2013 .

A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia

J. Herman, M. McDevitt, A. Chen, 2016, Clinical Cancer Research.

Inhibitory characteristics of prostaglandin F2α in the rat luteal cell

S. Gore, J. Luborsky, H. Behrman, 1983, Molecular and Cellular Endocrinology.

Clinical translation of epigenetics in cancer: eN-CORe—a report on the second workshop

R. Lotan, A. Zelent, S. Waxman, 2005, Molecular Cancer Therapeutics.

State of the Translational Science: Summary of Baltimore Workshop on Gene Re-expression As a Therapeutic Target in Cancer January 2003

M. Carducci, A. Zelent, S. Waxman, 2004 .

Differentiation therapy in poor risk myeloid malignancies: Results of a dose finding study of the combination bryostatin-1 and GM-CSF.

Zhe Zhang, S. Piantadosi, J. Kowalski, 2011, Leukemia research.

Changes in Promoter Methylation and Gene Expression in Patients with MDS and MDS-AML Treated with 5-Azacitidine and Sodium Phenylbutyrate.

M. Grever, J. Herman, S. Baylin, 2004 .

Secondary Myeloid Neoplasms in Older Women with Breast Cancer after Radiotherapy: A Population-Based Study

G. Abel, C. Gross, Xiaomei Ma, 2015 .

Myelodysplastic Syndromes and Acute Myeloid Leukemia in Prostate Cancer Patients after Radiotherapy, a Population-Based Study

C. Gross, Xiaomei Ma, S. Gore, 2015 .

Outcome of patients with low‐risk and intermediate‐1‐risk myelodysplastic syndrome after hypomethylating agent failure: A report on behalf of the MDS Clinical Research Consortium

H. Kantarjian, G. Garcia-Manero, T. Kadia, 2015, Cancer.

Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide.

D. Loegering, K. Flatten, N. T. Dai, 2009, Blood.

The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia

D. Arber, J. Cortes, M. Tallman, 2020, Journal for ImmunoTherapy of Cancer.

Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology.

F. Appelbaum, K. Gregory, D. Arber, 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

Purine modulation of LH action in gonadal cells.

A. T. Williams, S. Gore, M. Polan, 1983, Journal of steroid biochemistry.

Antagonistic interactions of adenosine and prostaglandin F2 alpha modulate acute responses of luteal cells to luteinizing hormone.

S. Gore, H. Behrman, S. Preston, 1982, Endocrinology.

Alteration of transmembrane sodium and potassium gradients inhibits the action of luteinizing hormone in the luteal cell.

S. Gore, H. Behrman, 1984, Endocrinology.

CALCIUM: A CELLULAR MEDIATOR OF LUTEOLYSIS

S. Gore, H. Behrman, L. Dorflinger, 1984 .

Adenine-derived purines increase adenosine triphosphate (ATP) levels in the luteal cell: evidence that cell levels of ATP may limit the stimulation of adenosine 3',5'-monophosphate accumulation by luteinizing hormone.

S. Gore, T. Brennan, H. Behrman, 1983, Endocrinology.

Autoimmune Phenomena in Patients with Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia

M. Saif, S. Gore, Jon L Hopkins, 2002, Leukemia & lymphoma.

Disseminated, yet dissembled: Rare infections behind the veil of classical hairy cell leukemia.

S. Gore, Mina L. Xu, R. Shallis, 2020, Leukemia research.

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.

Valeria Santini, Robert Schoch, Pierre Fenaux, 2009, The Lancet. Oncology.

Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia

M. Krem, C. Hourigan, M. Aljurf, 2021, Blood advances.

Clinical Features and HLA Association of 5-Aminosalicylate (5-ASA)-induced Nephrotoxicity in Inflammatory Bowel Disease.

M. Tremelling, M. Parkes, C. Lees, 2016, Journal of Crohn's & colitis.

Myeloid sarcoma, chloroma, or extramedullary acute myeloid leukemia tumor: A tale of misnomers, controversy and the unresolved.

R. Gale, K. Roberts, S. Gore, 2020, Blood reviews.

Arsenic trioxide - An old drug rediscovered.

S. Gore, A. Emadi, 2010, Blood reviews.

Acute myeloid leukemia is characterized by Wnt pathway inhibitor promoter hypermethylation

Michael A McDevitt, J. Herman, M. McDevitt, 2010, Leukemia & lymphoma.

NCCN Acute Myeloid Leukemia , Version 3 . 2017 Clinical Practice Guidelines in Oncology

F. Appelbaum, K. Gregory, D. Arber, 2017 .

Future directions for the use of hypomethylating agents.

G. Garcia-Manero, S. Gore, 2005, Seminars in hematology.

Report of an international working group to standardize response criteria for myelodysplastic syndromes.

B. Cheson, P. Greenberg, H. Kantarjian, 2000, Blood.

p21WAF1/CIP1 induction by 5-azacytosine nucleosides requires DNA damage

J. Herman, S. Baylin, S. Gore, 2008, Oncogene.

Emerging drugs for the treatment of myelodysplastic syndrome

S. Gore, Philip J Nivatpumin, 2005, Expert opinion on emerging drugs.

Myelodysplastic syndromes.

C. Bloomfield, M. Millenson, H. Deeg, 2011, Journal of the National Comprehensive Cancer Network : JNCCN.

Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia.

B. Cheson, P. Greenberg, H. Kantarjian, 2006, Blood.

New ways to use DNA methyltransferase inhibitors for the treatment of myelodysplastic syndrome.

S. Gore, 2011, Hematology. American Society of Hematology. Education Program.

Enhancing survival outcomes in the management of patients with higher-risk myelodysplastic syndromes.

Evelyn R. Hermes-DeSantis, S. Gore, E. Hermes-DeSantis, 2009, Cancer control : journal of the Moffitt Cancer Center.

Oral Valacyclovir as Prophylaxis against Herpes Simplex Virus Reactivation During High Dose Chemotherapy for Leukemia

S. Piantadosi, R. Orlowski, S. Gore, 2004, Leukemia & lymphoma.

Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia.

H. Dombret, G. Mufti, P. Fenaux, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Role of allogeneic transplantation for FLT3/ITD acute myeloid leukemia: outcomes from 133 consecutive newly diagnosed patients from a single institution.

M. McDevitt, Richard J. Jones, B. Smith, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

The Clinical Application of Targeting Cancer through Histone Acetylation and Hypomethylation

J. Herman, M. Carducci, J. Gilbert, 2004, Clinical Cancer Research.

Chronic myelomoncytic leukemia: Are we finally solving the identity crisis?

S. Gore, A. Nazha, A. Zeidan, 2016, Blood reviews.

Modifying histones to tame cancer: clinical development of sodium phenylbutyrate and other histone deacetylase inhibitors

M. Carducci, S. Gore, Michael A Carducci, 2000, Expert opinion on investigational drugs.

Lack of Association Between Costs of Care and Overall Survival (OS) Among Medicare Beneficiaries with Myelodysplastic Syndromes (MDS) in the United States (US)

C. Gross, Xiaomei Ma, S. Gore, 2015 .

Epigenetics in Cancer: A Hematological Perspective

Tae Kon Kim, S. Gore, A. Zeidan, 2016, PLoS genetics.

Human AML cells in NOD/SCID mice: engraftment potential and gene expression

P. Meltzer, S. Gore, D. Small, 2002, Leukemia.

BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma.

A. K. Church, J. Cerhan, A. Feldman, 2015, Blood.

Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms.

M. Grever, J. Herman, S. Baylin, 2006, Cancer research.

Modulating Gene Expression as a Therapeutic Approach in the Treatment of AML

S. Gore, H. Carraway, T. Fandy, 2007 .

DNMT3A Haploinsufficiency Transforms FLT3ITD Myeloproliferative Disease into a Rapid, Spontaneous, and Fully Penetrant Acute Myeloid Leukemia.

David E. Muench, M. L. Le Beau, N. Salomonis, 2016, Cancer discovery.

Epigenetic targets in human neoplasms.

S. Gore, T. Fandy, 2010, Epigenomics.

Progressive chromatin repression and promoter methylation of CTNNA1 associated with advanced myeloid malignancies.

Wei Zhang, Jeanne Kowalski, Hua-Ling Tsai, 2009, Cancer research.

Aberrant Epigenetic and Genetic Marks Are Seen in Myelodysplastic Leukocytes and Reveal Dock4 as a Candidate Pathogenic Gene on Chromosome 7q*

O. Abdel-Wahab, A. Melnick, Jinghang Zhang, 2011, The Journal of Biological Chemistry.

prognostic markers in acute leukemia Evaluation of Apaf-1 and procaspases-2, -3, -7, -8, and -9 as potential

Y. Lazebnik, John Calvin Reed, S. Krajewski, 2013 .

Evaluation of Apaf-1 and procaspases-2, -3, -7, -8, and -9 as potential prognostic markers in acute leukemia.

Y. Lazebnik, John Calvin Reed, S. Krajewski, 2000, Blood.

Future directions in myelodysplastic syndrome: newer agents and the role of combination approaches.

Evelyn R. Hermes-DeSantis, S. Gore, E. Hermes-DeSantis, 2008, Cancer control : journal of the Moffitt Cancer Center.

MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation.

Lucy Skrabanek, John M Greally, J. Licht, 2009, Blood.

Failure of three novel regimens to improve outcome for patients with relapsed or refractory acute myeloid leukaemia: a report from the Eastern Cooperative Oncology Group

M. Tallman, S. Gore, M. Othus, 2010, British journal of haematology.

Inhibited apoptosis and drug resistance in acute myeloid leukaemia

Richard J. Jones, B. Smith, S. Gore, 1998, British Journal of Haematology.

Flavopiridol synergizes TRAIL cytotoxicity by downregulation of FLIPL

R. K Srivastava, S. Gore, D. Ross, 2007, Cancer Chemotherapy and Pharmacology.

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia

J. Friedberg, M. Shipp, P. L. Bergsagel, 2016, Journal of Immunotherapy for Cancer.

A phase 2 trial of high dose lenalidomide in patients with relapsed/refractory higher‐risk myelodysplastic syndromes and acute myeloid leukaemia with trilineage dysplasia

B. Smith, S. Gore, H. Carraway, 2017, British journal of haematology.

Six (or more) drugs in search of a mechanism: DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes.

S. Gore, 2006, Journal of the National Comprehensive Cancer Network : JNCCN.

Practice Patterns and Real-Life Outcomes for Patients with Acute Promyelocytic Leukemia

Xiaomei Ma, S. Gore, J. Bewersdorf, 2020 .

Myelodysplastic Syndromes: DIAGNOSIS AND EMERGING THERAPIES

S. Gore, A. List, 2005 .

Phase 1 study of the histone deacetylase inhibitor entinostat plus clofarabine for poor-risk Philadelphia chromosome-negative (newly diagnosed older adults or adults with relapsed refractory disease) acute lymphoblastic leukemia or biphenotypic leukemia.

B. Smith, J. Karp, J. Trepel, 2021, Leukemia research.

DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes.

S. Gore, E. Griffiths, 2008, Seminars in hematology.

A dose-finding study of liposomal daunorubicin with CVP (COP-X) in advanced NHL.

S. Goodman, I. Flinn, S. Gore, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Current therapy of myelodysplastic syndromes.

S. Gore, A. Zeidan, Y. Linhares, 2013, Blood reviews.

State of the Translational Science

M. Carducci, A. Zelent, S. Waxman, 2004, Clinical Cancer Research.

Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia.

M. Grever, L. Grochow, R. Donehower, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

A phase 2 study of vorinostat in acute myeloid leukemia

John F. DiPersio, Vivek Roy, J. Dipersio, 2009, Haematologica.

Sequential Flavopiridol, Cytosine Arabinoside, and Mitoxantrone: A Phase II Trial in Adults with Poor-Risk Acute Myelogenous Leukemia

Richard J. Jones, B. Smith, J. Karp, 2007, Clinical Cancer Research.

Differentiation therapy in poor risk myeloid malignancies: Results of companion phase II studies.

J. Kowalski, Richard J. Jones, B. Smith, 2016, Leukemia research.

Commentary: topoisomerases as targets in acute leukemia: I, II, I plus II or none?

S. Malek, S. Gore, 2003, Leukemia research.

Factors Affecting Topotecan Sensitivity in Human Leukemia Samples a

L. Grochow, R. Donehower, Richard J. Jones, 1996, Annals of the New York Academy of Sciences.

A phase I and pharmacological study of topotecan infused over 30 minutes for five days in patients with refractory acute leukemia.

R. Donehower, S. Baker, S. Kaufmann, 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

Effi cacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes : a randomised , open-label , phase III study

J. Byrd, G. Mufti, J. Bennett, 2012 .

Long-term follow-up of intensive ara-C-based chemotherapy followed by bone marrow transplantation for adult acute lymphoblastic leukemia: impact of induction Ara-C dose and post-remission therapy.

S. Piantadosi, J. Karp, S. Kaufmann, 2002, Leukemia research.

Expanding access to early phase trials: the CATCH-UP.2020 experience

M. Mooney, S. Gore, L. Rubinstein, 2022, JNCI cancer spectrum.

Early death in patients with acute promyelocytic leukemia. Proceedings from a live roundtable at the 2010 American Society of Hematology Annual Meeting, December 4–7, 2010, Orlando, Florida.

F. Lo‐Coco, M. Tallman, M. Sanz, 2011, Clinical advances in hematology & oncology : H&O.

Flow cytometric detection of rare normal human marrow cells with immunophenotypes characteristic of acute lymphoblastic leukemia cells.

C. Civin, K. Stone, S. Gore, 1992, Leukemia.

Telomere biology disorder prevalence and phenotypes in adults with familial hematologic and/or pulmonary presentations.

T. Walsh, M. King, R. Collins, 2020, Blood advances.

Detection of minimal residual T cell acute lymphoblastic leukemia by flow cytometry.

S. Goodman, M. Kastan, C. Civin, 1990, Journal of immunological methods.

Germ line tissues for optimal detection of somatic variants in myelodysplastic syndromes.

M. Walter, R. Bejar, L. Moscinski, 2018, Blood.

Cell microarray platform for anticancer drug development

E. Sausville, W. Telford, S. Hewitt, 2007 .

Epigenetic Therapy in Acute Myeloid Leukemia: Current and Future Directions.

Tae Kon Kim, S. Gore, A. Zeidan, 2015, Seminars in hematology.

Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1st International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS).

Tae Kon Kim, R. Bejar, O. Abdel-Wahab, 2023, Blood reviews.

Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies.

Chris A. Nasrallah, J. Herman, J. Licht, 2009, Blood.

Lost in translation? Ten years of development of histone deacetylase inhibitors in acute myeloid leukemia and myelodysplastic syndromes

S. Gore, N. Vey, T. Prebet, 2016, Expert opinion on investigational drugs.

Challenging the concept of de novo acute myeloid leukemia: Environmental and occupational leukemogens hiding in our midst.

S. Gore, N. Deziel, R. Shallis, 2020, Blood reviews.

Temporal patterns and predictors of receiving no active treatment among older patients with acute myeloid leukemia in the United States: A population‐level analysis

Xiaomei Ma, S. Gore, J. Bewersdorf, 2019, Cancer.

New Strategies in Acute Promyelocytic Leukemia: Moving to an Entirely Oral, Chemotherapy-Free Upfront Management Approach

S. Gore, A. Zeidan, 2014, Clinical Cancer Research.

Oncologist volume and outcomes in older adults diagnosed with diffuse large B cell lymphoma

C. Gross, Xiaomei Ma, S. Gore, 2018, Cancer.

Demethylation demystification.

S. Gore, L. Suarez, 2013, Blood.

Clinical Outcomes of Older Patients (pts) with Acute Myeloid Leukemia (AML) Receiving Hypomethylating Agents (HMAs): A Large Population-Based Study in the United States

Xiaomei Ma, S. Gore, J. Bewersdorf, 2019, Blood.

Myelodysplastic Syndromes: Pathophysiology

S. Gore, E. Warlick, 2011 .

Extended follow-up of autologous bone marrow transplantation with 4-hydroperoxycyclophosphamide (4-HC) purging for indolent or transformed non-Hodgkin lymphomas.

Richard J. Jones, S. Gore, A. Blackford, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

DNA Demethylating Agents and Histone Deacetylase Inhibitors in Hematologic Malignancies

S. Gore, H. Carraway, T. Fandy, 2007, Cancer journal.

Immunomodulation with pomalidomide at early lymphocyte recovery after induction chemotherapy in newly diagnosed AML and high-risk MDS

H. Hackl, L. Gondek, J. Karp, 2020, Leukemia.

Pharmacokinetics and Pharmacodynamics with Extended Dosing of CC-486 in Patients with Hematologic Malignancies

B. Skikne, G. Garcia-Manero, S. Gore, 2015, PloS one.

Classification, treatment goals, and management principles for myelodysplastic syndromes.

S. Gore, 2004, Cancer control : journal of the Moffitt Cancer Center.

Higher-risk myelodysplastic syndromes with del(5q): does the del(5q) matter?

S. Gore, E. Gorshein, Urs Weber, 2020, Expert review of hematology.

Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure.

B. Esterni, B. Quesnel, P. Fenaux, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Working Group (IWG) response criteria in myelodysplasia Clinical application and proposal for modification of the International

P. Greenberg, H. Kantarjian, J. Bennett, 2009 .

Pharmacokinetics of 5-azacitidine administered with phenylbutyrate in patients with refractory solid tumors or hematologic malignancies.

M. Carducci, J. Gilbert, S. Baker, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lobular neutrophilic panniculitis associated with DNA methyltransferase inhibitors in the treatment of myeloid disease

S. Gore, G. Panse, S. Cowper, 2019, Journal of cutaneous pathology.

Clinical outcomes and characteristics of patients with TP53-mutated acute myeloid leukemia or myelodysplastic syndromes: a single center experience*

Tae Kon Kim, S. Gore, J. Bewersdorf, 2020, Leukemia & lymphoma.

Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States.

Xiaomei Ma, S. Gore, J. Bewersdorf, 2020, Blood advances.

Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia.

B. Skikne, H. Kantarjian, G. Garcia-Manero, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term survival of older patients with MDS treated with HMA therapy without subsequent stem cell transplantation.

Xiaomei Ma, S. Gore, A. Zeidan, 2018, Blood.

Umbrella Trial in Myeloid Malignancies: The Myelomatch National Clinical Trials Network Precision Medicine Initiative

J. Radich, B. Freidlin, B. Wood, 2022, Blood.

Molecular Biology of Myelodysplasia

S. Gore, Philip J Nivatpumin, 2006 .

Shuangge Ma, C. Gross, Xiaomei Ma, 2016, Cancer.

Myelodysplastic Syndromes and Acute Myeloid Leukemia After Radiotherapy for Prostate Cancer: A Population‐Based Study

C. Gross, Xiaomei Ma, S. Gore, 2017, The Prostate.

Clinical effectiveness of DNA methyltransferase inhibitors and lenalidomide in older patients with refractory anemia with ring sideroblasts: a population-based study in the United States

Xiaomei Ma, S. Gore, J. Bewersdorf, 2021, Leukemia & lymphoma.

Association of provider experience and clinical outcomes in patients with myelodysplastic syndromes receiving hypomethylating agents

Xiaomei Ma, S. Gore, J. Bewersdorf, 2020, Leukemia & lymphoma.

Hypomethylating agent (HMA) therapy use and survival in older adults with Refractory Anemia with Excess Blasts (RAEB) in the United States (USA): a large propensity score-matched population-based study†

Xiaomei Ma, S. Gore, J. Bewersdorf, 2019, Leukemia & lymphoma.

Modest improvement in survival of patients with refractory anemia with excess blasts in the hypomethylating agents era in the United States

G. Abel, C. Gross, Xiaomei Ma, 2017, Leukemia & lymphoma.

Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes

G. Abel, C. Gross, Xiaomei Ma, 2016, British journal of haematology.

Second malignancies among older patients with classical myeloproliferative neoplasms treated with hydroxyurea

Xiaomei Ma, S. Gore, A. Zeidan, 2022, Blood advances.

Impact of the putative differentiating agents sodium phenylbutyrate and sodium phenylacetate on proliferation, differentiation, and apoptosis of primary neoplastic myeloid cells.

D. Samid, L. Weng, S. Gore, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

The impact of phlebotomy and hydroxyurea on survival and risk of thrombosis among older patients with polycythemia vera.

Xiaomei Ma, S. Gore, A. Zeidan, 2018, Blood advances.

Patients with FLT3/ITD AML May Benefit From Allogeneic Transplant In First Remission: Outcomes From a Consecutive Series of Patients at a Single Institution

M. McDevitt, J. Kowalski, Richard J. Jones, 2010 .

Risk of myeloid neoplasms after radiotherapy among older women with localized breast cancer: A population-based study

G. Abel, C. Gross, Xiaomei Ma, 2017, PloS one.

Agent Orange and dioxin-induced myeloid leukemia: a weaponized vehicle of leukemogenesis

S. Gore, R. Shallis, 2022, Leukemia & lymphoma.

A clandestine culprit with critical consequences: Benzene and acute myeloid leukemia.

S. Gore, N. Deziel, R. Shallis, 2020, Blood reviews.

Identification of growth factor-responsive acute myelogenous leukemia based on factor-dependence for survival and proliferation.

L. Weng, S. Gore, P. Burke, 1994, Leukemia.

What are the most promising new agents in myelodysplastic syndromes?

S. Gore, T. Prebet, P. Boddu, 2019, Current opinion in hematology.

Impact of exogenous growth factors on proliferation and chemosensitivity of minimal residual acute myeloid leukemia.

L. Weng, S. Gore, P. Burke, 1998, Leukemia & lymphoma.

Timed sequential therapy for acute myelogenous leukemia: Results of a retrospective study of 301 patients and review of the literature.

R. Varadhan, M. McDevitt, B. Smith, 2017, Leukemia research.

Molecular Testing in Myelodysplastic Syndromes for the Practicing Oncologist: Will the Progress Fulfill the Promise?

S. Gore, M. Sekeres, A. Nazha, 2015, The oncologist.

Tipifarnib (Zarnestra, R115777) as Maintenance Therapy for Adults in Complete Remission (CR) Following Induction and Consolidation Therapies for Poor-Risk Acute Myelogenous Leukemia (AML): A Phase II Trial.

B. Smith, J. Karp, J. Greer, 2005 .

Effects of azacitidine compared with conventional care regimens in elderly (≥ 75 years) patients with higher-risk myelodysplastic syndromes.

G. Mufti, P. Fenaux, E. Hellström-Lindberg, 2010, Critical reviews in oncology/hematology.

Phase II Trial of Tipifarnib as Maintenance Therapy in First Complete Remission in Adults with Acute Myelogenous Leukemia and Poor-Risk Features

B. Smith, J. Karp, J. Lancet, 2008, Clinical Cancer Research.

Phase II Trialof Tipifarnib asMaintenanceTherapy in First Complete Remission inAdultswithAcuteMyelogenous Leukemia andPoor-Risk Features

B. Smith, J. Karp, J. Lancet, 2008 .

Single cycle of arsenic trioxide-based consolidation chemotherapy spares anthracycline exposure in the primary management of acute promyelocytic leukemia.

R. Arceci, S. Gore, I. Gojo, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Health Care Use by Older Adults With Acute Myeloid Leukemia at the End of Life.

C. Gross, Xiaomei Ma, S. Gore, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Durable molecular remissions with a single cycle of timed sequential consolidation chemotherapy in acute promyelocytic leukemia

M. Grever, S. Piantadosi, W. Stock, 2005, American journal of hematology.

Molecular testing of isolated myeloid sarcoma allows successful FLT3-targeted therapy

D. Pucar, S. Gore, A. Zeidan, 2021, Annals of Hematology.

Active Oral Regimen for Elderly Adults with Newly Diagnosed Acute Myelogenous Leukemia (AML): Phase I Trial of Oral Tipifarnib (T) Combined with Oral Etoposide (E) for Adults ≥Age 70 Who Are Not Candidates for Traditional Cytotoxic Chemotherapy (TCC).

S. Malek, B. Smith, J. Karp, 2006 .

Myelodysplastic Syndrome (MDS) Displays Profound and Functionally Significant Epigenetic Deregulation Compared to Acute Myeloid Leukemia (AML) and Normal Bone Marrow Cells.

Chris A. Nasrallah, J. Licht, A. Melnick, 2007 .

Inhibitors of signaling in myelodysplastic syndrome.

S. Gore, 2004, Best practice & research. Clinical haematology.

Outcome of Patients (pts) Treated for Myelodysplastic Syndrome (MDS) and Secondary Acute Myeloid Leukemia (s AML) After Azacitidine (AZA) Failure

B. Esterni, P. Fenaux, S. Thépot, 2010 .

Consolidation Therapy with Blinatumomab Improves Overall Survival in Newly Diagnosed Adult Patients with B-Lineage Acute Lymphoblastic Leukemia in Measurable Residual Disease Negative Remission: Results from the ECOG-ACRIN E1910 Randomized Phase III National Cooperative Clinical Trials Network Trial

C. Mullighan, M. Liedtke, D. Arber, 2022, Blood.

Clinical roundtable monograph. Early death in patients with acute promyelocytic leukemia.

F. Lo‐Coco, M. Tallman, M. Sanz, 2011, Clinical advances in hematology & oncology : H&O.

Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy

R. Larson, F. Appelbaum, C. Willman, 2014, British journal of haematology.

Treatment of patients with acute promyelocytic leukemia: a consensus statement on risk-adapted approaches to therapy.

M. Tallman, F. Ravandi, M. Sanz, 2010, Clinical lymphoma, myeloma & leukemia.

Underutilization of guideline‐recommended supportive care among older adults with multiple myeloma in the United States

C. Gross, Xiaomei Ma, S. Gore, 2019, Cancer.

Quantification of 5-azacytidine in plasma by electrospray tandem mass spectrometry coupled with high-performance liquid chromatography.

M. Carducci, S. Baker, M. Rudek, 2004, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

MicroRNA: mIR-ly regulators of DNMT?

S. Gore, E. Griffiths, 2009, Blood.

Cytoprotective effects of hematopoietic growth factors on primary human acute myeloid leukemias are not mediated through changes in BCL-2, bax, or p21WAF1/CIP1.

Joseph A. DiGiuseppe, L. Weng, M. Kastan, 1999, In Vivo.

ROS 'n' roll: a bunch of JNK?

S. Gore, 2006 .

Myeloproliferative Disease into a Rapid, Spontaneous, and Fully Penetrant Acute Myeloid Leukemia

David E. Muench, M. L. Beau, N. Salomonis, 2016 .

Impact of in vivo administration of interleukin 3 on proliferation, differentiation, and chemosensitivity of acute myeloid leukemia.

S. Piantadosi, L. Weng, S. Gore, 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

How to Provide the Needed Protection from COVID-19 to Patients with Hematologic Malignancies.

Katie M. Campbell, M. Dhodapkar, A. Ribas, 2021, Blood cancer discovery.

Equitable Access to Clinical Trials: How Do We Achieve It?

L. Fashoyin-Aje, S. Gore, J. Baranda, 2023, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Evaluation of induction chemotherapies after hypomethylating agent failure in myelodysplastic syndromes and acute myeloid leukemia.

L. Pleyer, P. Fenaux, T. Cluzeau, 2018, Blood advances.

Randomized Phase II/III Study of DA-EPOCH-R +/- Venetoclax in Previously Untreated Double Hit Lymphoma: Initial Results from Alliance A051701

J. Friedberg, J. Leonard, S. Gore, 2021, Blood.

Prognostic understanding in acute leukemia: Patient-physician differences.

S. Gore, K. Adelson, A. Zeidan, 2018 .

Extended Dosing of Oral Azacitidine (CC-486) for 14 and 21 Days Provides More Effective Methylation Reversal Than a 7-Day Schedule

B. Skikne, G. Garcia-Manero, S. Gore, 2012 .

Safety and Efficacy of Oral Azacitidine (CC-486) Administered in Extended Treatment Schedules to Patients with Lower-Risk Myelodysplastic Syndromes

B. Skikne, S. Kambhampati, G. Garcia-Manero, 2012 .

Oral Azacitidine (AZA) Activity in Patients with Acute Myelogenous Leukemia (AML)

B. Skikne, G. Garcia-Manero, S. Gore, 2011 .